News

Start-up: Pfizer funds ex-workers
Enlarge image

BusinessUK

Start-up: Pfizer funds ex-workers

06.11.2012 - Ziarco has raised €21.1m in a series A financing round. The start-up from four former Pfizer colleagues gets the money from their former employer.

Ziarco Pharma Ltd. from Canterbury secured €21.1m (GBP16.8m) in a series A financing round. Investors are US venture fund Biotechnology Value Fund L.P. and other affiliates of BVF Partners L.P. (“BVF”) as well as Pfizer Venture Investments (“PVI”). Ziarco is a new clinical-stage biotechnology company founded by President and CEO Mike Yeadon, a former Vice President and Chief Scientific Officer of Pfizer’s Allergy and Respiratory Research Unit in Sandwich. Together with three former Pfizer colleagues, he directs the start-up which aims to develop innovative therapeutics targeting inflammatory and allergic diseases. One of the peers, CSO Steve Liu, claims that the most advanced clinical programme, ZPL-3893787 – a histamine H4 receptor (H4R) antagonist – could potentially be used to treat several major diseases, including asthma, allergic rhinitis, pain and a variety of inflammatory skin conditions. This programme is included in a deal made by Ziarco and Pfizer Inc. that promises the start-up exclusive worldwide rights to commercialise a range of clinical, preclinical and research assets. In return, Pfizer will receive equity as well as certain product-based milestone and royalty payments.

The lead compound of the H4R antagonist programme has completed a Phase I multiple ascending dose study. Other programmes in various stages of development include a clinical stage cytosolic phosholipase A2 (cPLA2) inhibitor, histamine H3 receptor antagonists possessing CNS-sparing properties as well as early-stage spleen tyrosine kinase (SYK) inhibitor molecules suitable for topical administration.

© eurobiotechnews.eu/ml

http://www.european-biotechnology-news.com/news/news/2012-04/start-up-pfizer-funds-ex-workers.html

BusinessSwitzerland

03.07.2015 Biotech giant Biogen is investing CHF 1bn in a new pharmaceutical production plant in the Swiss town of Luterbach. Noted as one of the world’s oldest biotech firms, the new plant will create up to 400 jobs.

Personalised MedicineNetherlandsBelgiumSpain

02.07.2015 Dutch biotech Amarna and Austrian Biomarker research centre CBmed have joined forces to develop several immunotherapies, including therapies against cancer and diabetes type 2. The joint venture will develop Amarna’s next generation viral vector platform.

M&ASwitzerland

30.06.2015 Pharma giant Novartis has bumped up its neuroscience portfolio with the recent purchase of Australian biotech Spinifex for a US$200m upfront payment plus US$500 in milestone payments. The acquisition is centred on Spinifex’ mid-stage pain drug EMA401.

Personalised MedicineGermany

25.06.2015 German immunotherapy expert BioNTech AG has partnered up with Europe’s largest engineering company Siemens to construct a manufacturing site for BioNTech’s personalised cancer vaccine.

Bioelectronic researchSweden

24.06.2015 Swedish scientists have created artificial neurons that are capable of mimicking the function of human nerve cells. The researchers hope that, once minituarised, they may one day be used to restore disturbed neural function.

FinancingLuxembourgItalySwitzerland

23.06.2015 Cosmo Pharmaceuticals is floating its majority-owned subsidiary Cassiopea at the Swiss Stock Exchange, with the aim to raise between CHF150m and CHF200m.

EventEUGermany

22.06.2015 For the 31st time, the ACHEMA has drawn the global chemical engineering and the process industry to Frankfurt. Although still overshadowed by petrol, the biobased economy is getting ready to step out into the limelight.

EventEU

17.06.2015 At the BIO convention in Philadelphia, the biotech industry celebrates new gene and cell therapies, and hails its unlikely superheroes.

ResearchUKSwitzerland

16.06.2015 Northern Ireland’s biopharma Almac Discovery is partnering up with Roche subsidiary Genentech in a two-year joint research programme to discover and develop cancer treatments.

M&ANorwayFinlandSweden

12.06.2015 The high-potential cancer immunotherapy market is fiercely fought, and small companies have trouble making their mark. Nordic companies Targovax and Oncos have joined forces to create a Nordic immuno-oncology champion named Polaris.

Events

All Events

Current issue

All issues

Product of the week

Products

Stock list

All quotes

TOP

  • MEDIGENE (D)10.45 EUR7.51%
  • WILEX (D)3.65 EUR5.49%
  • SUMMIT (UK)4.03 GBP3.87%

FLOP

  • 4SC (D)4.59 EUR-6.33%
  • BAVARIAN NORDIC (D)41.82 EUR-6.28%
  • BIOFRONTERA (D)2.06 EUR-5.50%

TOP

  • DBV Technologies (F)52.75 EUR22.8%
  • THERAMETRICS (CH)0.07 CHF16.7%
  • MEDIGENE (D)10.45 EUR16.6%

FLOP

  • CHRONTECH PHARMA (S)0.01 SEK-50.0%
  • NORDIC NANOVECTOR (N)25.20 NOK-26.5%
  • TRANSGENE (F)3.68 EUR-26.4%

TOP

  • 4SC (D)4.59 EUR345.6%
  • ADOCIA (F)65.40 EUR336.0%
  • WILEX (D)3.65 EUR319.5%

FLOP

  • CHRONTECH PHARMA (S)0.01 SEK-87.5%
  • ACTIVE BIOTECH (S)8.85 SEK-70.6%
  • NEOVACS (F)1.10 EUR-69.3%

No liability assumed, Date: 05.07.2015